Stay updated with breaking news from Oren Becher. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CHICAGO — Survivors of high-risk neuroblastoma face a substantial burden of late toxicity, according to study results presented at ASCO Annual Meeting.Prevalence of some late effects vary by treatment received, findings showed.
The combination of olaparib and the investigational ATR inhibitor ceralasertib induced antitumor responses in children and adolescents with DNA repair-deficient tumors, according to phase 1 results of the AcSé-ESMART trial.The data, presented at American Association for Cancer Research Annual Meeting, also showed ceralasertib (AZD6738, AstraZeneca) plus olaparib (Lynparza, AstraZeneca) — a
Researchers have developed a new drug delivery approach that uses nanoparticles to enable more effective and targeted delivery of anti-cancer drugs to treat brain tumors in children.
The cancer immunotherapy called CAR-T, has revolutionized the treatment of blood cancers. Doctors are now seeing signs it also may fight solid tumors.